Full Press Release Details
Alpha Tau to Participate
in Ladenburg's Oncology Innovators & Investors Symposium
JERUSALEM, December 6th,
2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative
alpha-radiation cancer therapy Alpha DaRT , today announced that CFO Raphi Levy will present at the Ladenburg
Oncology Innovators & Investors Symposium.
| Event: | Ladenburg Oncology Innovators & Investors Symposium |
| Format: | Presentation and 1-on-1 Meetings |
| Date: | December 12, 2024 |
| Time: | 11:00AM - 11:25AM EST |
| Location: | Virtual |
Please reach out to your Ladenburg representative to schedule 1-on-1
meetings with Mr. Levy.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company
that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology
was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed
to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When
the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with
the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor,
and to spare the healthy tissue around it.
Investor Relations Contact: IR@alphatau.com